ARGX 121
Alternative Names: ARGX-121Latest Information Update: 18 Mar 2024
At a glance
- Originator argenx
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 18 Mar 2024 argenx plans a clinical trial in in Autoimmune disorders in
- 05 Mar 2024 ARGX 121 is available for licensing as of 05 Mar 2024. https://www.argenx.com/innovation#antibody-engineering (argenx pipeline, March 2024)
- 05 Mar 2024 Preclinical trials in Autoimmune disorders in Netherlands (Parenteral) prior to February 2024